Precigen Stock

Precigen EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Precigen (PGEN) as of Aug 11, 2026 is -7.07. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -12.92 — a change of -45.28% (higher).

EV/EBIT

-7.07

YoY

-45.28%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Precigen is 2026 -7.07 . EV/EBIT (Enterprise Value to EBIT) of Precigen was 2025 -12.92 . It decreases by -45.28% higher compared to the previous year.

The Precigen EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-9.86 base
Jan 1, 2020
-21.06 base
Jan 1, 2021
-8.04 base
Jan 1, 2022
-4.31 base
Jan 1, 2023
-3.34 base
Jan 1, 2024
-2.43 base
Jan 1, 2025
-5.30 base
Jan 1, 2026 (e)
-17.96 base
YEARPRICE-TO-EBIT
2026 est -17.96
2025 -5.30
2024 -2.43
2023 -3.34
2022 -4.31
2021 -8.04
2020 -21.06
2019 -9.86
2018 -1.08
2017 -6.41
2016 -14.48
2015 -15.05
2014 -24.37
2013 -24.15
2012 -
2011 -
Access this data via the Eulerpool API

Precigen Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Precigen's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Precigen's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Precigen's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Precigen grows earnings faster than its peers.

Precigen Stock analysis

What does Precigen do? Precigen Inc is a biotechnology company headquartered in Germantown, Maryland, USA. The company was founded in 1991 under the name Human Genome Sciences Inc and became the first company in the industry to unlock genetic genes for drug development. In 2019, the company was renamed Precigen Inc. The company specializes in the development of cell and gene therapy products based on the latest advances in regenerative medicine. The goal is to treat diseases that have been difficult or even considered incurable through gene therapy, genome sequencing, and artificial intelligence. Precigen is divided into several divisions: Precigen ActoBio, Precigen Genome, Precigen RegenX, and Precigen Triple Gem. The divisions differ in product development and target application areas. Precigen ActoBio focuses on the development of biological therapies for autoimmune diseases. The company is working on an oral immunotherapy that can treat respiratory and inflammatory bowel diseases. The product is in the testing phase and if all goes well, approval could be within reach. Precigen Genome specializes in genome sequencing. The data from the genes is decoded to develop better medical diagnoses and therapies. Precigen Genome's services range from sequencing genomic information to uncovering further details to interpreting genome data. Precigen RegenX develops gene therapy products for the treatment of rare but severe genetic diseases. The aim is to modify specific genes in the body to achieve a cure or alleviate symptoms. An example of a product from Precigen RegenX is a gene therapy for hemophilia. This product is being tested in phase II clinical trials and could represent a true revolution in treatment. Precigen Triple Gem is the company's newest division, founded in 2020. It is a research and development project focused on novel cancer therapies. The main focus is on the development of CAR-T cells that can recognize and destroy various types of cancer cells. The company has already achieved promising results. The products from Precigen aim to simplify the treatment of severe diseases and minimize side effects through integration into molecular medicine. Patient safety is the top priority. To ensure this, strict testing phases are undergone and there is close monitoring of product development. Precigen's business strategy is based on collaboration with other companies and institutions. The company works with large pharmaceutical companies to support production, distribution, and marketing of the products, among other partnerships. Another important partnership is with universities and research institutions, which help the company in developing new technologies, improving production processes, and conducting clinical trials. This collaboration leads to faster research insights and a larger pool of knowledge and know-how. Precigen is also committed to recruiting the best talent and qualified personnel in the field of biotechnology. Overall, Precigen is an extremely innovative and promising company in the field of regenerative medicine and gene therapy. The company relies on a clever business strategy and forward-thinking partnerships to develop even better therapies for serious, previously incurable diseases in the future. Precigen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Precigen stock

EV/EBIT (Enterprise Value to EBIT) of Precigen is -7.07 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Precigen changed from -12.92 to -7.07, representing a -45.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Precigen since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Precigen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Precigen

All Key Metrics — Precigen